Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Management and Treatment of Hepatitis C Viral Infection: Table 7

for Health Care Providers

Table 7.Comparison of Sustained Virologic Response Rates (SVR) for Peginterferon Alfa-2b and Interferon Alfa Combination Therapies Given Over 48 Weeks

Back to Therapy for Previously Untreated Patients

* Peginterferon alfa-2b 1.5 mcg/kg/wk and ribavirin 800 mg/day.

IFN 3 million U three times weekly plus ribavirin 1,000 or 1,200 mg/day.

Compared to interferon alfa plus ribavirin.

§Defined as >2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL.

Statistical analysis not performed; data from Peg-Intron package insert.

||Defined as ≤2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL.

PATIENT GROUPSVR
Peginterferon alfa-2b plus ribavirin*Interferon alfa plus ribavirin
Overall54% (p=0.01)47%
HCV genotype 142% (p<0.05)33%
High viral
titer§
30%29%
Low viral
titer||
Not reportedNot reported
HCV genotype 2 or 382%79%
HCV genotypes 4-650%38%